Efficacy, Safety and Predictive Biomarkers of Oncolytic Virus Therapy in Solid Tumors: A Systematic Review and Meta-Analysis.

Although the OS difference in the overall OPTiM population narrowly missed significance ( p = 0.051) file-(Ref) [ 43 ], a pre-specified subgroup analysis of patients with earlier-stage metastatic disease showed a marked survival benefit: in stage IIIB–IVM1a melanoma, median OS was 41.1 months with intralesional T-VEC vs. 21.5 months with GM-CSF (HR 0.57, p < 0.001) [ 75 ].

also in 36 other papers

18%, p = 0.002) compared to ipilimumab monotherapy [ 45 ], with a nonsignificant trend toward prolonged PFS (median 8.2 vs. 6.4 months, HR 0.83).

also in 1,972 other papers

Although the result did not reach statistical significance, the direction of the effect suggests a potential survival benefit for some patients.

also in 50,127 other papers

The pooled hazard ratio was 2.77, with a 95% confidence interval of 1.85 to 4.16, and a highly significant p -value (<0.01).

also in 42,942 other papers